Stocksigma LogoStocksigma Logo

Novartis India Outlines Strategic Shift Post ChrysCapital Acquisition and Key M&A

Following ChrysCapital Group's acquisition of a 70.68% stake from Novartis AG at ₹860.64 per share on 29th Jul'26, Novartis India Limited (NIL) outlined

Novartis India Outlines Strategic Shift Post ChrysCapital Acquisition and Key M&A

Novartis India Ltd · Investor Presentation · 11 Sept 2026, 9:20 pm

Novartis India Outlines Strategic Shift Post ChrysCapital Acquisition and Key M&A Following ChrysCapital Group's acquisition of a 70.68% stake from Novartis AG at ₹860.64 per share on 29th Jul'26, Novartis India Limited (NIL) outlined its strategic transformation. NIL is transitioning from partner-led distribution to an in-house model with a 900+ member field force covering ~150,000 HCPs, incurring one-time transition costs across Q2-Q4 FY27. Expanding its portfolio, NIL acquired the 'Minipress' trademark from Pfizer for ₹1,250 Cr and entered an exclusive ₹10 Cr in-licensing pact for retina drugs Accentrix and Pagenax. NIL will rebrand within 120 days.

Original exchange filing (PDF)

More announcements from Novartis India Ltd

All Novartis India Ltd announcements